Breast Journal最新文献

{"title":"Candidate Oligo Therapeutic Target, miR-330-3p, Induces Tamoxifen Resistance in Estrogen Receptor-Positive Breast Cancer Cells via HDAC4","authors":"Meng Zhang,&nbsp;Mei Wang,&nbsp;Zhiming Jiang,&nbsp;Ziyi Fu,&nbsp;Jingjing Ma,&nbsp;Sheng Gao","doi":"10.1155/2023/2875972","DOIUrl":"10.1155/2023/2875972","url":null,"abstract":"<div>\u0000 <p>Tamoxifen is a drug used for treating breast cancer (BC), especially for individuals diagnosed with estrogen receptor-positive (ER+) BC. Its prolonged use could reduce the risk of recurrence and significantly lengthen the survival rate of BC patients. However, an increasing number of patients developed resistance to tamoxifen treatment, which reduced therapeutic efficiency and caused substandard prognosis. Therefore, the exploration of the molecular processes involved in tamoxifen resistance (TR) is urgently required. This investigation aimed to elucidate the relationship of microRNA-330 (miR-330-3p) with the TR of BC. There is little information on miR-330-3p′s link with drug-resistant BC, although it is well known to regulate cell proliferation and apoptosis. Primarily, miR-330-3p expression in parental BC (MCF7/T47D), TR (MCF7-TR), and T47D/TR cell lines was detected by qRT-PCR. Then, the impact of miR-330-3p on the TR of BC cells was assessed by a cell proliferation assay. Lastly, dual-luciferase reporter, qRT-PCR, and western blot assessments were carried out to identify histone deacetylase 4 (HDAC4) as the potential miR-330-3p target gene. The data indicated that miRNA-330 was overexpressed in TR ER+ BC cells and its overexpression could induce TR. Furthermore, miRNA-330 could also reduce the expression of HDAC4, which is closely linked to TR, and overexpression of HDAC4 could reverse miRNA-330-induced drug resistance. In summary, miR-330-3p could induce TR of ER+ BC cells by downregulating HDAC4 expression, which might be a novel marker of TR and a possible treatment target against BC patients who are tamoxifen-resistant.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10650376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating Low HER2 Status in Invasive Breast Carcinoma via HER2 Immunohistochemistry, with HER2 FISH Correlation: A Cohort of 112 Patients","authors":"Gokce Deniz Ardor,&nbsp;Miglena K. Komforti,&nbsp;Helena Hanna,&nbsp;Onur Ibanoglu,&nbsp;Abigail Lochala,&nbsp;Aziza Nassar","doi":"10.1155/2023/9725647","DOIUrl":"10.1155/2023/9725647","url":null,"abstract":"<div>\u0000 <p><i>Introduction</i>. Recent trials demonstrated clinically significant benefits in HER2-nonamplified breast cancer with HER2-low expression using novel anti-HER2 antibody-drug conjugates. Thus, HER2-low breast cancer was proposed as a separate diagnostic entity. Herein, we reclassify HER2-negative cancers according to the new HER2-low category using a modified system and further investigate HER2-very-low expression. <i>Methods</i>. 114 HER2 immunohistochemistry (IHC)-negative invasive breast tumors were identified from the pathology database of Mayo Clinic, Jacksonville, FL, between January 2019 and August 2022. Two blinded breast pathologists (BP) independently rescored HER2 IHC slides at 200x and 400x magnification. Discordant cases between the two BPs were rescored together. The most recent 2018 ASCO/CAP HER2 scoring criteria were used. HER2 (0) was subdivided into HER2 (absent) and HER2 (very low). HER2 FISH testing was performed in all cases. <i>Results</i>. The cohort comprised of 38 (33.3%) HER2 (0) and 76 (66.7%) HER2 (1+) tumors. The first round of rescoring at 200x and 400x magnification resulted in 17 (14.9%) HER2 (absent), 31 (27.2%) HER2 (very low), and 64 (56.2%) HER2 (1+) and 2 (1.8%) HER2 (2+) tumors by BP1 and 20 (17.5%) HER2 (absent), 33 (28.9%) HER2 (very low), and 61 (53.5%) HER2 (1+) tumors by BP2. The combined final rescoring by BP1 and BP2 was as follows: 15 (13.2%) HER2 (absent), 35 (30.7%) HER2 (very low), 63 (55.3%) HER2 (1+), and 1 (0.9%) HER2 (2+) cases. A comparison of the first round of rescoring between two BPs showed substantial agreement with Cohen’s kappa value of 0.67. Both comparisons of first rescoring by BP1 and by BP2 to combined final rescoring showed almost perfect agreement with Cohen’s kappa value of 0.83.Follow-up FISH studies showed one amplified tumor. <i>Conclusion</i>. Our data support the need for finer granularity, classification, and understanding of HER2-low breast cancers. We also show that reproducibility between trained BP can be obtained, albeit with scoring at high power and low threshold for showing challenging interpretations.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473890/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10224753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hormonal-Receptors-Positive and HER2-Negative Patients with Metastatic Breast Cancer Treated with First-Line Palbociclib and Hormonal Therapy: Impact of First-Cycle Neutropenia and Dose Reduction on Therapeutic Outcome","authors":"Khaled Abd Elaziz Ahmed Elnaghi,&nbsp;Hosam Ali Alghanmi,&nbsp;Shereef Ahmed Elsamany,&nbsp;Fathia Almarzoki,&nbsp;Mohamed Elsafty,&nbsp;Mohammad Jaffal","doi":"10.1155/2023/8994954","DOIUrl":"10.1155/2023/8994954","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. CDK 4/6 inhibitors with hormonal therapy are the standard first-line therapy in metastatic hormonal receptors (HR)-positive and HER2-negative breast cancer. This study aims to assess the impact of neutropenia with 1st cycle, dose reduction, HER2-low status, and other clinicopathological factors on survival outcomes with the first-line palbociclib and hormonal therapy. <i>Patients and Methods</i>. In this retrospective study, we recruited patients with metastatic HR-positive and HER2-negative breast cancer. Neutropenia with 1st cycle, palbociclib dose reduction in addition to different clinicopathological and survival data were checked in patients’ medical records. Survival outcomes were compared according to the abovementioned factors. <i>Results</i>. We recruited 150 patients who received first-line palbociclib with hormonal therapy. 86% of patients developed 1st cycle neutropenia which was more common in patients with high Ki67. Dose reduction was recorded in 46.7% of patients and it was more common in patients with higher Allred scores (scores 7–8). The median progression-free survival (PFS) of the study group was 22 months. No significant difference was observed in PFS according to the 1st cycle of neutropenia or grade of neutropenia. Similarly, no difference in PFS according to palbociclib dose reduction and HER2 low status was observed. Only the Allred score and having a single site of metastasis had an independent significant relation with PFS. The median overall survival (OS) of the study group was 39 months. No significant difference was observed in OS according to the 1st cycle neutropenia, grade of neutropenia, palbociclib dose reduction, and HER2-low status. Only the Allred score and having a single site of metastasis had an independent significant relation with OS. In addition, no difference was observed in PFS and OS according to ECOG PS (2 vs. 0-1) or menopausal status. <i>Conclusion</i>. No significant impact of the 1st cycle neutropenia, dose reduction, having ECOG PS2, menopausal status, or HER2 low status on survival outcome was observed. Survival outcome was significantly better in patients with single metastatic sites and higher ER-Allred scores.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10169139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of Carbon Localization for Invasive Breast Cancer: An Institutional Experience","authors":"Etienne El-Helou,&nbsp;Christine Eddy,&nbsp;Simona Picchia,&nbsp;Carine Van de Merckt,&nbsp;Magali Radermeker,&nbsp;Michel Moreau,&nbsp;Filip De Neubourg,&nbsp;Denis Larsimont,&nbsp;Isabelle Veys,&nbsp;C. Florin Pop","doi":"10.1155/2023/4082501","DOIUrl":"10.1155/2023/4082501","url":null,"abstract":"<div>\u0000 <p><i>Introduction</i>. The final oncological and aesthetic results of breast-conserving surgery (BCS) are influenced by the precise localization of breast cancer (BC) tumors and by the quality of the intraoperative margin assessment technique. This study aimed to assess the effectiveness of the carbon localization (CL) technique by determining the success rate of BC identification and the proportion of adequate complete resection of BC lesions. <i>Methods</i>. We conducted a cross-sectional retrospective study of patients treated with primary BCS for invasive BC who underwent CL of their BC lesion at the Jules Bordet Institute between January 2015 and December 2017. Descriptive statistics with categorical and continuous variables were used. The success rate of tumor identification and the rate of adequate excision were calculated using the test of percentages for independent dichotomous data. <i>Results</i>. This study included 542 patients with 564 nonpalpable BC lesions. The median pathological tumor size was 12 mm. Of these, 460 were invasive ductal carcinomas. Most of the tumors were of the luminal subtype. CL was performed using ultrasound guidance in 98.5% of cases. The median delay between CL and surgery was 5 days, with 46% of the patients having CL one day before surgery. The lumpectomy weighed 38 g on average, with a median diameter of the surgical sample at 6 cm and a median volume of 44 cm³ (6–369). One-stage complete resection was successfully performed in 93.4% of cases. In 36% of cases, an intraoperative re-excision was performed, based on intraoperative macroscopic pathological margin evaluation. The tumor was identified in 98.9% of cases in the breast surgical specimen. <i>Conclusion</i>. This study demonstrated high success rates for BC tumor identification (99%) and one-stage complete resection (93.4%) after BCS and CL. These results show that CL is an effective, simple, and inexpensive localization technique for successful excision of BC lesions during BCS.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9886791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The praxe: a disciplinary apparatus for entering into the world of Academia in Portugal].","authors":"Lía Zóttola","doi":"10.18294/sc.2023.4537","DOIUrl":"10.18294/sc.2023.4537","url":null,"abstract":"","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"17 1","pages":"e4537"},"PeriodicalIF":1.9,"publicationDate":"2023-07-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11930325/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85236560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy of Low-Kilovoltage X-Rays Intraoperative Radiation as Boost for Breast Cancer: A Systematic Review and Meta-Analysis","authors":"Yuanjian Fan,&nbsp;Ruiwan Chen,&nbsp;Ying Lu,&nbsp;Ying Lin,&nbsp;Yunjian Zhang,&nbsp;Nan Shao,&nbsp;Shenming Wang,&nbsp;Dahong Nie,&nbsp;Zhen Shan","doi":"10.1155/2023/9035266","DOIUrl":"10.1155/2023/9035266","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Intraoperative radiotherapy (IORT) is a novel promising technology that may replace external beam radiation therapy (EBRT) as boost for patients receiving breast-conserving surgery. To better evaluate the efficacy of IORT using low-kilovoltage (low-kV) X-rays as boost, we presented this meta-analysis according to the PRISMA checklist. <i>Methods</i>. Studies reported survival outcomes of intraoperative radiation using low-kilovoltage X-rays system (Intrabeam®, Carl Zeiss Meditec, Dublin, CA, USA) as boost were identified through electronic bibliographic database: PUBMED. The meta-analysis module in Stata (16.0) is used to pool the studies. A Poisson regression model is used to predict a 5-year local recurrence rate. <i>Results</i>. Twelve studies including 3006 cases were included in the final analysis, with a median follow-up of 55 months weighted by sample size. The pooled local recurrence rate is 0.39% per person-year (95% CI: 0.15%–0.71%), with a low degree of heterogeneity (<i>I</i>² = 0%). The predicted 5-year local recurrence rate was 3.45%. No difference in pooled local recurrence rate was found between non-neoadjuvant patients studies and neoadjuvant patients studies (0.41% per person-year vs. 0.58% per person-year, <i>P</i> = 0.580). <i>Conclusions</i>. This study shows that low-kV IORT is an effective method as boost in breast cancer patients, with a low pooled local recurrence rate and low predicted 5-year local recurrence rate. Besides, no difference in the local recurrence rate was found between non-neoadjuvant patients studies and neoadjuvant patients studies. Low-kV IORT boost may be a promising alternative to EBRT boost in the future, which is being tested in the ongoing TARGIT-B trial.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9815799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting","authors":"Efthymia Skafida,&nbsp;Angeliki Andrikopoulou,&nbsp;Evangelos Terpos,&nbsp;Christos Markellos,&nbsp;Savvina Moustafa,&nbsp;Dimitrios Pectasides,&nbsp;Meletios-Athanasios Dimopoulos,&nbsp;Flora Zagouri,&nbsp;Dimitrios Vassilopoulos","doi":"10.1155/2023/3614296","DOIUrl":"10.1155/2023/3614296","url":null,"abstract":"<div>\u0000 <p><i>Background</i>. Third-generation aromatase inhibitors (AIs) are the mainstay of treatment in hormone receptor (HR)-positive breast cancer. Even though it is considered to be a well-tolerated therapy, AI-induced musculoskeletal symptoms are common and may be accused for treatment discontinuation. Recently, selective cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors changed the therapeutic setting, and currently, ribociclib, palbociclib, and abemaciclib are all approved in combination with nonsteroidal AIs in patients with ER-positive, HER2-negative advanced or metastatic breast cancer. This systematic review aims to identify the frequency of aromatase inhibitor-associated musculoskeletal syndrome (AIMSS) in the adjuvant setting in patients under AI monotherapy compared to patients under combination therapy with AIs and CDK4/6 inhibitors and demonstrate the underlying mechanism of action. <i>Methods</i>. This study was performed in accordance with PRISMA guidelines. The literature search and data extraction from all randomized clinical trials (RCTs) were done by two independent investigators. Eligible articles were identified by a search of MEDLINE and ClinicalTrial.gov database concerning the period 2000/01/01–2021/05/01. <i>Results</i>. Arthralgia was reported in 13.2 to 68.7% of patients receiving AIs for early-stage breast cancer, while arthralgia induced by CDK4/6 inhibitors occurred in a much lower rate [20.5–41.2%]. Bone pain (5–28.7% vs. 2.2–17.2%), back pain (2–13.4% vs. 8–11.2%), and arthritis (3.6–33.6% vs. 0.32%) were reported less frequently in patients receiving the combination of CDK4/6 inhibitors with ET. <i>Conclusions</i>. CDK4/6 inhibitors might have a protective effect against joint inflammation and arthralgia occurrence. Further studies are warranted to investigate arthralgia incidence in this population.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10247331/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9982460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effect of Adjuvant Radiotherapy on One- and Two-Stage Prosthetic Breast Reconstruction and on Autologous Reconstruction: A Multicenter Italian Study among 18 Senonetwork Breast Centres","authors":"Andrea Vittorio Emanuele Lisa,&nbsp;Marzia Salgarello,&nbsp;Alessandra Huscher,&nbsp;Fabio Corsi,&nbsp;Daniele Piovani,&nbsp;Federica Rubbino,&nbsp;Stefania Andreoletti,&nbsp;Giovanni Papa,&nbsp;Francesco Klinger,&nbsp;Corrado Tinterri,&nbsp;Alberto Testori,&nbsp;Marta Scorsetti,&nbsp;Paolo Veronesi,&nbsp;Maria Cristina Leonardi,&nbsp;Mario Rietjens,&nbsp;Umberto Cortinovis,&nbsp;Valeria Summo,&nbsp;Emanuele Rampino Cordaro,&nbsp;Pier Camillo Parodi,&nbsp;Paolo Persichetti,&nbsp;Mauro Barone,&nbsp;Giorgio De Santis,&nbsp;Matteo Murolo,&nbsp;Michele Riccio,&nbsp;Angelica Aquinati,&nbsp;Francesco Cavaliere,&nbsp;Nicola Vaia,&nbsp;Giulia Pagura,&nbsp;Erica Dalla Venezia,&nbsp;Franco Bassetto,&nbsp;Vincenzo Vindigni,&nbsp;Luigi Ciuffreda,&nbsp;Maria Alessandra Bocchiotti,&nbsp;Alberto Sciarillo,&nbsp;Nadia Renzi,&nbsp;Graziano Meneghini,&nbsp;Tajna Kraljic,&nbsp;Andrea Loreti,&nbsp;Lucio Fortunato,&nbsp;Valentina Pino,&nbsp;Valeriano Vinci,&nbsp;Marco Klinger","doi":"10.1155/2023/6688466","DOIUrl":"10.1155/2023/6688466","url":null,"abstract":"<div>\u0000 <p><i>Purpose</i>. In modern breast cancer treatment, a growing role has been observed for breast reconstruction together with an increase in clinical indications for postmastectomy radiotherapy (PMRT). Choosing the optimum type of reconstructive technique is a clinical challenge. We therefore conducted a national multicenter study to analyze the impact of PMRT on breast reconstruction. <i>Methods</i>. We conducted a retrospective case-control multicenter study on women undergoing breast reconstruction. Data were collected from 18 Italian Breast Centres and stored in a cumulative database which included the following: autologous reconstruction, direct-to-implant (DTI), and tissue expander/immediate (TE/I). For all patients, we described complications and surgical endpoints to complications such as reconstruction failure, explant, change in type of reconstruction, and reintervention. <i>Results</i>. From 2001 to April 2020, 3116 patients were evaluated. The risk for any complication was significantly increased in patients receiving PMRT (aOR, 1.73; 95% CI, 1.33–2.24; <i>p</i> &lt; 0.001). PMRT was associated with a significant increase in the risk of capsular contracture in the DTI and TE/I groups (aOR, 2.24; 95% CI, 1.57–3.20; <i>p</i> &lt; 0.001). Comparing type of procedures, the risk of failure (aOR, 1.82; 95% CI, 1.06–3.12, <i>p</i> = 0.030), explant (aOR, 3.34; 95% CI, 3.85–7.83, <i>p</i> &lt; 0.001), and severe complications (aOR, 2.54; 95% CI, 1.88–3.43, <i>p</i> &lt; 0.001) were significantly higher in the group undergoing DTI reconstruction as compared to TE/I reconstruction. <i>Conclusion</i>. Our study confirms that autologous reconstruction is the procedure least impacted by PMRT, while DTI appears to be the most impacted by PMRT, when compared with TE/I which shows a lower rate of explant and reconstruction failure. The trial is registered with NCT04783818, and the date of registration is 1 March, 2021, retrospectively registered.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9949365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Lobular Neoplasia Diagnosed by Core Biopsy","authors":"Chinmay Jani,&nbsp;Margaret Lotz,&nbsp;Sarah Keates,&nbsp;Yasha Gupta,&nbsp;Alexander Walker,&nbsp;Omar Al Omari,&nbsp;Arshi Parvez,&nbsp;Dipesh Patel,&nbsp;Maria Gnata,&nbsp;John Perry,&nbsp;Leila Khorashadi,&nbsp;Lisa Weissmann,&nbsp;Susan E. Pories","doi":"10.1155/2023/8185446","DOIUrl":"10.1155/2023/8185446","url":null,"abstract":"<div>\u0000 <p>Lobular neoplasia (LN) involves proliferative changes within the breast lobules. LN is divided into lobular carcinoma in situ (LCIS) and atypical lobular hyperplasia (ALH). LCIS can be further subdivided into three subtypes: classic LCIS, pleomorphic LCIS, and LCIS with necrosis (florid type). Because classic LCIS is now considered as a benign etiology, current guidelines recommend close follow-up with imaging versus surgical excision. The goal of our study was to determine if the diagnosis of classic LN on core needle biopsy (CNB) merits surgical excision. This is a retrospective, observational study conducted at Mount Auburn Hospital, Cambridge, MA, from May 17, 2017, through June 30, 2020. We reviewed the data of breast biopsies conducted at our hospital over this period and included patients who were diagnosed with classic LN (LCIS and/or ALH) and excluded patients having any other atypical lesions on CNB. All known cancer patients were excluded. Of the 2707 CNBs performed during the study period, we identified 68 women who were diagnosed with ALH or LCIS on CNB. CNB was performed for an abnormal mammogram in the majority of patients (60; 88%) while 7(10.3%) had an abnormal breast magnetic resonance imaging study (MRI), and 1 had an abnormal ultrasound (US). A total of 58 patients (85%) underwent excisional biopsy, of which 3 (5.2%) showed malignancy, including 2 cases of DCIS and 1 invasive carcinoma. In addition, there was 1 case (1.7%) with pleomorphic LCIS and 11 cases with ADH (15.5%). The management of LN found on core biopsy is evolving, with some advocating surgical excision and others recommending observation. Our data show a change in diagnosis with excisional biopsy in 13 (22.4%) of patients with 2 cases of DCIS, 1 invasive carcinoma, 1 pleomorphic LCIS, and 9 cases of ADH, diagnosed on excisional biopsy. While ALH and classic LCIS are considered benign, the choice of ongoing surveillance versus excisional biopsy should be made with shared decision making with the patient, with consideration of personal and family history, as well as patient preferences.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9802726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting of Ki-67 Expression Level Using Diffusion-Weighted and Synthetic Magnetic Resonance Imaging in Invasive Ductal Breast Cancer","authors":"Liying Zhang,&nbsp;Jisen Hao,&nbsp;Jia Guo,&nbsp;Xin Zhao,&nbsp;Xing Yin","doi":"10.1155/2023/6746326","DOIUrl":"10.1155/2023/6746326","url":null,"abstract":"<div>\u0000 <p><i>Objectives</i>. To investigate the association between quantitative parameters generated using synthetic magnetic resonance imaging (SyMRI) and diffusion-weighted imaging (DWI) and Ki-67 expression level in patients with invasive ductal breast cancer (IDC). <i>Method</i>. We retrospectively reviewed the records of patients with IDC who underwent SyMRI and DWI before treatment. Precontrast and postcontrast relaxation times (T1, longitudinal; T2, transverse), proton density (PD) parameters, and apparent diffusion coefficient (ADC) values were measured in breast lesions. Univariate and multivariate regression analyses were performed to screen for statistically significant variables to differentiate the high (≥30%) and low (&lt;30%) Ki-67 expression groups. Their performance was evaluated by receiver operating characteristic (ROC) curve analysis. <i>Results</i>. We analyzed 97 patients. Multivariate regression analysis revealed that the high Ki-67 expression group (<i>n</i> = 57) had significantly higher parameters generated using SyMRI (pre-T1, <i>p</i> = 0.001) and lower ADC values (<i>p</i> = 0.036) compared with the low Ki-67 expression group (<i>n</i> = 40). Pre-T1 showed the best diagnostic performance for predicting the Ki-67 expression level in patients with invasive ductal breast cancer (areas under the ROC curve (AUC), 0.711; 95% confidence interval (CI), 0.609–0.813). <i>Conclusions</i>. Pre-T1 could be used to predict the pretreatment Ki-67 expression level in invasive ductal breast cancer.</p>\u0000 </div>","PeriodicalId":56326,"journal":{"name":"Breast Journal","volume":"2023 1","pages":""},"PeriodicalIF":1.9,"publicationDate":"2023-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098409/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9323177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}